Two cases of olanzapine-induced reversible neutropenia

被引：35

作者：

Steinwachs, A

Grohmann, R

Pedrosa, F

Rüther, E

Schwerdtner, I

机构：

[1] Univ Munich, Psychiat Klin, Dept Psychiat, D-80336 Munich, Germany

[2] Hosp Psychiat, Weinsberg, Germany

[3] Univ Gottingen, Dept Psychiat, D-3400 Gottingen, Germany

[4] Lilly Deutschland, Bad Homburg, Germany

来源：

PHARMACOPSYCHIATRY | 1999年 / 32卷 / 04期

关键词：

D O I：

10.1055/s-2007-979222

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Olanzapine is a tricyclic neuroleptic agent that due to structural similarities was expected to be a safe alternative to clozapine, which has a 0.5 -2% risk of agranulocytosis. So far, only rare cases of leukocytopenia and thrombocytopenia have become known. In the association,,Drug Safety in Psychiatry", which is made up of 25 German psychiatric hospitals, two cases of olanzapine-induced neutropenia occurred in patients with chronic schizophrenia. The adverse drug reaction was noticed 17 days after the first intake of olanzapine in case 1 and more than 5 months after the first intake in case 2. in the second case, a reexposure to olanzapine caused the neutrophil cells to decrease again. There were no clinical signs of an infection, and the blood cell counts increased immediately to normal ranges after discontinuation of olanzapine. No special treatment was necessary.

引用

页码：154 / 156

页数：3

共 18 条

[1] CLOZAPINE-INDUCED AGRANULOCYTOSIS - INCIDENCE AND RISK-FACTORS IN THE UNITED-STATES [J].

ALVIR, JMJ ;

LIEBERMAN, JA ;

SAFFERMAN, AZ ;

SCHWIMMER, JL ;

SCHAAF, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03) :162-167

[2] CLOZAPINE-INDUCED AGRANULOCYTOSIS - SITUATION REPORT UP TO AUGUST 1976 [J].

ANDERMAN, B ;

GRIFFITH, RW .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 11 (03) :199-201

[3]

Beasley CM, 1997, J CLIN PSYCHIAT, V58, P13

[4] Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial [J].

Beasley, CM ;

Sanger, T ;

Satterlee, W ;

Tollefson, G ;

Tran, P ;

Hamilton, S ;

Green, A ;

Dott, S ;

Pfister, G ;

Roxas, L ;

Small, J ;

Thomas, M ;

Ames, D ;

Schooler, N ;

Baker, R ;

Levine, R ;

Fabre, L ;

Friedel, R ;

Safferman, A ;

Lieberman, J ;

Stahl, S .

PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :159-167

[5] Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial [J].

Beasley, CM ;

Hamilton, SH ;

Crawford, AM ;

Dellva, MA ;

Tollefson, GD ;

Tran, PV ;

Blin, O ;

Beuzen, JN .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 (02) :125-137

[6] Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].

Beasley, CM ;

Tollefson, G ;

Tran, P ;

Satterlee, W ;

Sanger, T ;

Hamilton, S ;

Fabre, L ;

Small, J ;

Ereshefsky, L ;

True, J ;

Nemeroff, C ;

Risch, SC ;

Perry, PJ ;

Potkin, SG ;

Borison, RL ;

James, S ;

Meltzer, HY ;

Iqbal, N ;

Fann, WE ;

Gewirtz, GR ;

Landbloom, R ;

RoyByrne, PP ;

Tuason, VB ;

Carman, JS ;

Stokes, PE ;

Williams, R ;

Ancill, RJ ;

MacEwan, GW ;

Gujavarty, KS ;

Jones, B ;

Lohr, JB .

NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123

[7]

Casey DE, 1997, J CLIN PSYCHIAT, V58, P55

[8] Olanzapine - A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses [J].

Fulton, B ;

Goa, KL .

DRUGS, 1997, 53 (02) :281-298

[9] Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program:: Methods and first results for tricyclic antidepressants and SSRI [J].

Grohmann, R ;

Rüther, E ;

Engel, RR ;

Hippius, H .

PHARMACOPSYCHIATRY, 1999, 32 (01) :21-28

[10]

GROHMANN R, 1988, ARCH GEN PSYCHIAT, V45, P789

← 1 2 →